The spread, treatment, and prevention of HIV-1: evolution of a global pandemic

MS Cohen, N Hellmann, JA Levy, K DeCock… - The Journal of clinical …, 2008‏ - jci.org
The most up-to-date estimates demonstrate very heterogeneous spread of HIV-1, and more
than 30 million people are now living with HIV-1 infection, most of them in sub-Saharan …

The antibody response against HIV-1

J Overbaugh, L Morris - Cold Spring …, 2012‏ - perspectivesinmedicine.cshlp.org
Neutralizing antibodies (NAbs) typically play a key role in controlling viral infections and
contribute to the protective effect of many successful vaccines. In the case of HIV-1 infection …

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

BF Haynes, PB Gilbert, MJ McElrath… - … England Journal of …, 2012‏ - Mass Medical Soc
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

S Rerks-Ngarm, P Pitisuttithum… - … England Journal of …, 2009‏ - Mass Medical Soc
Background The development of a safe and effective vaccine against the human
immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. Methods In a …

Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy

SN Byrareddy, J Arthos, C Cicala, F Villinger, KT Ortiz… - Science, 2016‏ - science.org
Antiretroviral drug therapy (ART) effectively suppresses replication of both the
immunodeficiency viruses, human (HIV) and simian (SIV); however, virus rebounds soon …

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads

J Mabuka, R Nduati, K Odem-Davis, D Peterson… - PLoS …, 2012‏ - journals.plos.org
There are limited data describing the functional characteristics of HIV-1 specific antibodies in
breast milk (BM) and their role in breastfeeding transmission. The ability of BM antibodies to …

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

SD Neidich, Y Fong, SS Li, DE Geraghty… - The Journal of Clinical …, 2019‏ - jci.org
HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombinant
adenovirus serotype 5 (rAd5) in circumcised, Ad5-seronegative men and transgendered …

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection

JH Kim, JL Excler, NL Michael - Annual review of medicine, 2015‏ - annualreviews.org
RV144 remains the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1
acquisition. The prespecified analysis of immune correlates of risk showed that antibodies …

Single-chain soluble BG505. SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env

IS Georgiev, MG Joyce, Y Yang, M Sastry… - Journal of …, 2015‏ - journals.asm.org
Similar to other type I fusion machines, the HIV-1 envelope glycoprotein (Env) requires
proteolytic activation; specifically, cleavage of a gp160 precursor into gp120 and gp41 …

Progress in HIV vaccine development

DC Hsu, RJ O'Connell - Human vaccines & immunotherapeutics, 2017‏ - Taylor & Francis
An HIV-1 vaccine is needed to curtail the HIV epidemic. Only one (RV144) out of the 6 HIV-1
vaccine efficacy trials performed showed efficacy. A potential mechanism of protection is the …